News & Updates

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025 by

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025

Gallstone disease ups IBD risk

20 Jan 2025

People with gallstone disease are at higher risk of inflammatory bowel disease (IBD), regardless of other traditional risk factors, according to a study.

Gallstone disease ups IBD risk

20 Jan 2025

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025 by

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025

Anti-TNFs may reduce GDM risk in pregnant women with IBD

19 Jan 2025

Pregnant women with inflammatory bowel disease (IBD) who used antitumour necrosis factor (anti-TNF) therapy are at reduced risk of developing gestational diabetes mellitus (GDM), reports a study.

Anti-TNFs may reduce GDM risk in pregnant women with IBD

19 Jan 2025

IBD linked to increased risk of hidradenitis suppurativa

18 Jan 2025 by

Inflammatory bowel disease (IBD) is associated with an increased risk of hidradenitis suppurativa (HS), according to a study presented at AIBD 2024.

IBD linked to increased risk of hidradenitis suppurativa

18 Jan 2025

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025 by

Mirikizumab helps improve health-related quality of life (HRQoL) in Crohn’s disease (CD) patients, including those who have not had success with a biologic therapy, according to data from the phase III VIVID-1 study.

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

15 Jan 2025 by

Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

15 Jan 2025

Ozanimod delivers real-world clinical benefits in ulcerative colitis

14 Jan 2025 by

Treatment with ozanimod (oza) attains high efficacy rates in real-world clinical practice at week 12 for advanced therapy (AT)-naive patients with moderate-to-severe ulcerative colitis (UC) and at week 26 for those with AT exposure, as shown by initial results from POLARIS, an ongoing phase IV open-label study.

Ozanimod delivers real-world clinical benefits in ulcerative colitis

14 Jan 2025

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

11 Jan 2025

Patients with inflammatory bowel disease (IBD) who achieve a normal C-reactive protein (CRP) and endoscopic healing exhibit significantly higher ustekinumab trough levels, reveals a study. A cutoff level of 4.8 µg/mL predicts CRP normalization.

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

11 Jan 2025

Cirrhosis, portal hypertension worsen bowel prep for colonoscopy

10 Jan 2025

A recent study has observed poorer Boston Bowel Preparation Scale (BBPS) scores and longer cecal intubation times in patients with cirrhosis undergoing screening colonoscopy. Those who are not obese also have a lower rate of polyp detection.

Cirrhosis, portal hypertension worsen bowel prep for colonoscopy

10 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

No increase in CV risk with JAKi vs TNFi for IBD

No increase in CV risk with JAKi vs TNFi for IBD

Gallstone disease ups IBD risk

Gallstone disease ups IBD risk

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Anti-TNFs may reduce GDM risk in pregnant women with IBD

Anti-TNFs may reduce GDM risk in pregnant women with IBD

IBD linked to increased risk of hidradenitis suppurativa

IBD linked to increased risk of hidradenitis suppurativa

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

Ozanimod delivers real-world clinical benefits in ulcerative colitis

Ozanimod delivers real-world clinical benefits in ulcerative colitis

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

Cirrhosis, portal hypertension worsen bowel prep for colonoscopy

Cirrhosis, portal hypertension worsen bowel prep for colonoscopy